Sivelestat added to standard steroid therapy during an NMOSD attack

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study evaluates the safety and tolerability of intravenous sivelestat sodium hydrate given with standard steroid pulse therapy in adults having an acute NMOSD attack. Participants receive 4.8 mg/kg/day of sivelestat as a continuous infusion for 5 days, alongside the study's steroid regimen, with follow-up for 28 days to monitor safety and neurological outcomes. The study also explores whether adding sivelestat to steroids improves neurological recovery compared with baseline expectations. Safety assessments include adverse events, labs, vital signs, and other clinically relevant data. The trial is conducted at Kyushu University Hospital and is led by Kyushu University with no listed collaborators.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients diagnosed with anti-AQP4 antibody-positive NMOSD according to the international diagnostic criteria for NMOSD (Wingerchuk, Neurology 2015).
2. Patients experiencing a relapse including any of the following, with the relapse occurring within 14 days of obtaining consent:

   i. Unilateral or bilateral optic neuritis ii. Myelitis
3. Patients whose FS domain has worsened by at least 1 point due to relapse.
4. Patients with one or more relapse lesions identified on MRI (however, if the relapse is considered to have occurred in the same location as an existing MRI lesion neurologically, identification of a new relapse lesion is not required).
5. Patients aged 18 years or older at the time of obtaining consent.
6. Female patients of childbearing potential who agree to use appropriate contraception from the time of obtaining consent until 180 days after the end of investigational product administration.
7. Male patients who agree to use appropriate contraception until 90 days after the end of investigational product administration.
8. Patients who can provide written informed consent.

Exclusion Criteria:

1. Patients with multi-organ dysfunction involving 4 or more organs.
2. Patients with severe chronic respiratory disease.
3. Patients with autoimmune diseases other than NMOSD that are expected to require additional treatment during the study period.
4. Patients with active systemic bacterial, viral, or fungal infections.
5. Patients who have received either or both of the following prior treatments after an NMOSD relapse:

   i. Two or more courses of steroid pulse therapy ii. Plasmapheresis iii. High-dose immunoglobulin therapy
6. Patients with severe hepatic dysfunction.
7. Patients with alcohol dependence, drug dependence, or psychiatric disorders that would interfere with study participation.
8. Patients who have received other investigational drugs within 3 months prior to obtaining consent.
9. Pregnant women, women suspected of being pregnant, or breastfeeding women.
10. Patients with allergies to the investigational product or concomitant medications.
11. Patients with severe allergies or a history of severe allergies.
12. Patients with suicidal tendencies meeting any of the following criteria:

    i. Within 1 month prior to the screening assessment, there was suicidal behavior or ideation corresponding to "Yes" for Item 4 (Active suicidal ideation -some intent to act, but no specific plan) or Item 5 (Active suicidal ideation -specific plan and intent) of the Columbia-Suicide Severity Rating Scale (C-SSRS). (For subjects who only met Items 1-3, inclusion may be permitted at the discretion of the principal investigator or sub-investigator.) ii. Any suicidal behavior based on Item 6 of the C-SSRS occurred within the past 3 months.
13. Other patients judged inappropriate by the principal investigator or sub-investigator.

Where it's running

• Kyushu University Hospital
  Fukuoka, Japan Recruiting

Study contacts

• Study coordinator: Mitsuru Watanabe, MD, PhD
• Email: shinkein@med.kyushu-u.ac.jp
• Phone: +81926425340

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Acute treatments for AQP4-positive NMOSD attacks

  This project will test whether adding eculizumab or IVIG to high-dose IV steroid pulses helps adults with AQP4-positive NMOSD during an acute attack.

  Recruiting Phase 4 Chinese PLA General Hospital · Beijing · NCT07410039

• Pitavastatin in PLGA Nanoparticles for Retinitis Pigmentosa safety test

  This Phase 1 study tests whether an intravenous pitavastatin nanoparticle formulation is safe for adults with retinitis pigmentosa.

  Recruiting Phase 1 Kyushu University · Fukuoka · NCT07774975

• Adding sotatercept to usual therapy for adults with Eisenmenger syndrome or unrepaired shunt-related pulmonary arterial hypertension

  This study will test whether giving sotatercept in addition to standard PAH medicines helps adults with Eisenmenger syndrome or unrepaired shunt-associated pulmonary arterial hypertension that has not improved enough on vasodilators.

  Recruiting at 10 sites Phase 4 Kyushu University · Fukuoka, Not Required For This Country and 9 other locations · NCT07356778

• Testing GAIA-102 for difficult-to-treat pediatric cancers

  This study is testing a new treatment called GAIA-102 for children with tough-to-treat cancers to see if it’s safe and how much of it they should get.

  Recruiting Phase 1 Kyushu University · Fukuoka, Fukuoka · NCT05608148

• Treatment for advanced gastrointestinal cancer with malignant ascites

  This study is testing a new treatment called GAIA-102, alone and with pembrolizumab, to see if it helps people with advanced gastrointestinal cancer and fluid buildup in the abdomen feel better.

  Recruiting Phase 1/2 Kyushu University · Fukuoka, Fukuoka · NCT05438459

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.